Experts say the emerging tech can dramatically accelerate advances in drug discovery, diagnostics and precision medicine.

Q4 2025 earnings call recap: 2026 revenue guidance, TearCare reimbursement milestone, OMNI growth outlook, margins and risks—read now.

The new report details how life sciences organizations are responding to regulatory change, resource constraints, and fragmented systems. ST. PAUL, MN / ACCESS Newswire / March 4, 2026 / Grand Avenue ...

The Triangle’s life sciences sector is in the midst of one of the most significant growth waves in its history. But as the ...

Every life sciences company knows that patient safety is non negotiable, but the way safety is managed—and the value ...

AICA currently supports auditing against 21 CFR Parts 11, 211, and 600, each mapped at the section and subsection levels.

Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.

The Penn Museum and the Academy of Natural Sciences of Drexel University have discontinued their long-running summer camp ...

Learn more about whether Exact Sciences Corporation or Avidity Biosciences, Inc. is a better investment based on AAII's A+ ...

Upcycle, swap and style sustainably with the Natural Sciences Council! Bring a tee or tote to revamp and learn how small ...